Novo Nordisk
PROD · 2026-08-20 01:15 EDT
Novo Nordisk · Rare Disease Onboarding

Learning Material

You Can Talk To

None of this is read alone. Stop Lola mid-sentence, ask what a word means the moment you hit it, or say "again" and hear it a different way. The material answers back, and you are the one steering.

An Onboarding Companion

For Life, Not For a Week

She remembers what you confirmed and what you found hard, and she is still here in a year — when a clinician asks you something you last thought about in your first week.

Where Your Expertise Starts

Not Where It Ends

Six modules are mapped and the first one is live: nineteen concepts of normal clotting, fifty-four answers to confirm out loud. What you build here is the floor everything after it stands on.

What to expect when you start talking

She Teaches By Voice

Speak normally, interrupt whenever
The glass paints itself as you ask
Nothing to click, nothing to scroll

19 Authored Concepts

What blood does, and what stops a bleed
The 1964 cascade, and why it survives
Where haemophilia breaks the sequence

95 Spoken Checks

She asks; you answer out loud
A wrong answer is never marked right
A concept closes when enough of it lands

Progress That Persists

Every confirmed check is recorded
Resume at the exact concept you left
Six modules mapped, module one live
Avatar
What this is

The curriculum, with someone to answer to.

Lola teaches the rare bleeding disorders programme out loud. Not a deck you scroll and not a video you finish — a walk through the material, one concept at a time, where she stops and asks you to say it back before either of you moves on.

That last part is the whole design. Reading a module and knowing it are different things, and the gap between them is invisible until someone asks you a question. Here someone always does. You cannot finish a concept by looking at it.

6
Modules
Clotting to field readiness
14
Screens
Module one, authored
37
Spoken checks
Answered out loud
The territory

One bleeding problem, four ways in.

Everything in this franchise ends in the same place — blood that will not stop — but each condition arrives there by a different route. Knowing which route you are looking at is most of the job.

Congenital haemophilia
A missing factor, inherited

Haemophilia A is a deficiency of factor eight; haemophilia B, factor nine. Both are X‑linked, both bleed into joints and muscles, and severity tracks how much factor is left. A is roughly five times more common than B.

Inhibitors
The treatment stops working

An antibody that neutralises the factor being infused, measured in Bethesda units. It is the complication that turns a managed condition back into an unmanaged one, and immune tolerance induction is the attempt to undo it.

Rare factor deficiencies
Factor seven and factor thirteen

Rarer, autosomal, and easier to miss. Factor thirteen is the trap — the clot forms normally and then falls apart hours later, so the routine coagulation screen comes back clean.

Acquired haemophilia
Not inherited at all

An autoantibody against a person’s own factor eight, arriving in adulthood with no family history. It bleeds into skin, mucosa and soft tissue rather than joints — and it is frequently missed until it is dangerous.

The programme

Six modules, in this order for a reason.

You learn the working system before any of the ways it breaks. Module one is built and live; the five after it are scoped, and the dashboard will show them as they land rather than pretending they are already here.

1
Normal Blood Clotting

What blood does, and how a healthy body stops bleeding. Nineteen concepts and ninety-five checks — live now.

2
Congenital Haemophilia A and B

Factor VIII and IX deficiency, the genetics, and how severity shows up as a bleeding phenotype.

3
Inhibitor Development and Management

Neutralising antibodies, Bethesda titres, and the immune tolerance induction protocols.

4
Extended Half-Life and Non-Factor Therapies

Fc‑fusion, PEGylation, and the bispecific antibody mimics that changed what prophylaxis looks like.

5
Prophylaxis and Bleed Management

Pharmacokinetic targeting, trough levels, and what actually happens during an acute bleed.

6
Clinical Communication and Field Readiness

Reading trial data honestly, and the HCP conversations you are actually being prepared for.

How a concept closes

Talk normally. Answer out loud.

She is voice‑first. The glass is not a slideshow you click through — it paints itself in response to what you ask, and you never need to touch it. What you do have to do is answer her.

“Start me at the beginning.”
She opens concept one and sets the map.
“Take me to the cascade model.”
Jump to any concept by name. The order is a path, not a lock.
“How am I doing?”
The roadmap, with every concept’s real state on it.
“I don’t follow.”
She takes another run at it, in plainer language.
“Slow down.” · “Go deeper.”
Pace and depth are yours. Say so mid‑sentence.
“Can we switch to Spanish?”
Voice and glass change together, same turn.
The one habit worth forming
Guess before she tells you.

When she asks you something, answer — even badly. Retrieving an answer, including a wrong one, is what makes it stick; reading the right answer straight away feels faster and works less well. She will not mark a wrong answer right to be kind, and a concept only closes when enough of its questions have been answered correctly at least once.

The boundary

What she will not do.

This material is internal, and not for distribution or detailing. Some of that boundary is built into her rather than left to your judgement.

Dosing

She will not speak dosing figures aloud. Ask about a regimen and she will explain the principle — why factor nine is dosed less often than factor eight, what a trough target is for — then route you to Medical Information for the numbers.

Patients

She will not advise on the management of a specific patient. She teaches a Medical Liaison; she does not stand in for a haematologist, and she will say so plainly rather than hedge.

Promotion

She will not make a promotional claim or compare products favourably. Where a product appears it appears as mechanism and indication, which is the same line scientific exchange holds you to.

Invention

She will not fill a gap with a plausible answer. If the curriculum does not cover something she says so, rather than reaching for something that sounds right — and she will not name a colleague, because no roster ships with her.

Behind every answer

One curriculum. Nothing else.

Her knowledge is a fixed corpus written from the module you are studying, and she searches it on every turn rather than recalling from memory. That is precisely why she can tell you when she does not know — there is a specific place she looked, and it came back empty.

what blood does plasma and formed elements haemostasis the vascular phase platelet adhesion activation and aggregation the platelet plug the 1964 cascade intrinsic and extrinsic reading the factors cofactors and enzymes PT and aPTT tissue factor initiation amplification the thrombin burst tenase and prothrombinase antithrombin, protein C and S TFPI fibrinolysis where haemophilia fits

If something here contradicts your training materials, the training materials win — tell your Field Director, and tell her.

Built on